Terence C. Flynn - Goldman Sachs Group Inc., Research Division
Can you just let us now in terms of the 10% market share that you're using, what's the denominator that you guys are using that? Is it somewhere between the 10,000 to 15,000 patients? And then second question, just remind us in terms of EU filing, do you think FOCUS data is going to be enough to get a European approval?
N. Anthony Coles - Chief Executive Officer, President and Director
Okay. On FOCUS, very quickly, I think the answer there is yes. This is actually a result of several conversations with the EMA, and it is an overall survival study. So importantly, it's one of the last times probably an overall survival study can be done in this population. So we think it's valuable. It's registration worthy, and are really, as I mentioned earlier, very excited about not just the completion of enrollment but the potential interim readout in the second half of next year. And then, Helen, with regard to the penetration, patient penetration?
Helen I. Torley - Chief Commercial officer and Executive Vice President
Yes, as we look at our addressable population, it is the 10,000 to 15,000 patients who have previously received bortezomib and IMiD and are progressing. So our estimate of 10% comes from our estimates of how many new patient starts we've had in the third quarter and also triangulated with some syndicated data that suggests that's the market share as well, so a couple of sources triangulating. But clearly, these are estimates. And as we get more weeks of data, we're going to continue to refine that.